Equities
Health CareHealth Care Equipment & Services
  • Price (JPY)2,539.00
  • Today's Change73.00 / 2.96%
  • Shares traded15.17m
  • 1 Year change+12.52%
  • Beta0.8469
Data delayed at least 20 minutes, as of Nov 30 2021 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, science, video and other products. The Company operates in five business segments. The Endoscopy segment provides gastrointestinal endoscopy, surgical endoscopy, endoscopy systems and repair services. The Therapeutic Equipment segment provides endoscopic treatment tools, energy devices, urology, gynecology and otolaryngology products. The Scientific segment provides biological microscope, industrial microscope, industrial endoscope and non-destructive inspection equipment. The Imaging segment provides digital cameras and recording machines. The Others segment is engaged in the manufacture and sale of biomaterials. The Company is also engaged in the financial investment business.

  • Revenue in JPY (TTM)827.10bn
  • Net income in JPY102.14bn
  • Incorporated1919
  • Employees31.65k
  • Location
    Olympus CorpShinjuku Monolith, 2-3-1, Nishi-ShinjukuSHINJUKU-KU 163-0914JapanJPN
  • Phone+81 333402111
  • Fax+81 333402062
  • Websitehttps://www.olympus.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Olympus Corp827.10bn102.14bn3.20tn31.65k31.057.1119.423.8779.4176.20643.10347.020.73231.795.9826,130,320.009.064.7012.296.7764.5464.1212.376.151.3428.440.428524.62-3.27-1.918.250.94220.979723.07
Terumo Corp675.18bn95.41bn3.65tn26.48k38.104.0224.175.40126.10126.10892.331,195.280.50741.805.5025,495,880.007.176.938.388.3953.6854.0114.1313.171.88165.880.217124.62-2.393.18-9.328.8020.368.26
FUJIFILM Holdings Corp2.40tn209.86bn4.64tn73.28k17.251.5814.011.93523.04523.045,982.185,714.160.6893.275.0832,756,930.005.834.477.355.9040.7840.378.466.571.42--0.177824.45-5.30-2.2844.989.267.859.00
Data as of Nov 30 2021. Currency figures normalised to Olympus Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

34.13%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 15 Jul 202078.89m6.07%
Baillie Gifford & Co.as of 30 Jun 202165.60m5.05%
Capital Research & Management Co. (World Investors)as of 30 Sep 202161.70m4.75%
ValueAct Capital Management LPas of 04 Jan 202155.01m4.23%
Nikko Asset Management Co., Ltd.as of 15 Jun 202142.08m3.24%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Jun 202137.31m2.87%
Daiwa Asset Management Co. Ltd.as of 29 Oct 202136.72m2.83%
The Vanguard Group, Inc.as of 05 Nov 202126.49m2.04%
Norges Bank Investment Managementas of 31 Dec 202019.87m1.53%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Nov 202119.75m1.52%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.